Philippines approves GMO golden rice for commercial production
By Staff,
GMWatch
| 07. 23. 2021
No independent health risk assessment was done; Farmer-scientist group MASIPAG condemns decision
The Philippines has approved GMO golden rice for commercial production. This is in spite of the fact that no independent data on the safety of this GMO for health and the environment have been published; that beta-carotene, which the rice is engineered to contain, is one of the commonest molecules in nature and numerous native plants contain high levels; and that the US FDA says that GMO golden rice doesn't contain enough beta-carotene to justify a health claim.
As Glenn Davis Stone and Dominic Glover point out, it is still unknown if the beta-carotene in GMO golden rice can even be converted to Vitamin A in the bodies of badly undernourished children. In addition, research shows that what beta-carotene there is in the rice degrades rapidly in storage. Cooking further degrades the beta-carotene.
Meanwhile, as the development of golden rice creeps along, the Philippines has managed to slash the incidence of Vitamin A deficiency by non-GMO methods.
The author of the France24 article below is clearly ignorant of these crucial facts.
1. Philippines approves GMO 'golden rice'...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.30.2026
A research program at the National Institutes of Health released the world’s largest database of human genomes and paired them with clinical data, officials announced Tuesday, paving the way for a new era of study in personalized medicine.
The All...
By Sarah Norcross, Sandy Starr, Amanda Cooney, and Anneliese Burton, BioNews | 07.06.2026
By Mustapha Bature Sallama, Modern Ghana | 06.11.2026
In much of West Africa, a woman who cannot bear children does not merely face a medical condition. She faces a verdict. Her marriage may unravel. Her community may turn cold. Her identity, in a social order that ties womanhood...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...